Mindfulness-Based Program Plus Amygdala and Insula Retraining (MAIR) for the Treatment of Women with Fibromyalgia : a Pilot Randomized Controlled Trial
Sanabria-Mazo, Juan P.. (Universitat Autònoma de Barcelona. Facultat de Psicologia)
Gasión, Virginia (Instituto de Investigación Sanitaria de Aragón)
Navarro-Gil, Mayte (Instituto de Investigación Sanitaria de Aragón)
Morillo, Héctor (Universidad de Zaragoza. Facultad de Psicología)
Colomer-Carbonell, Ariadna (Universitat Autònoma de Barcelona. Facultat de Psicologia)
Borràs, Xavier (Universitat Autònoma de Barcelona. Facultat de Psicologia)
Tops, Mattie (Leiden University. Developmental and Educational Psychology Unit)
Luciano, Juan V. (Parc Sanitari Sant Joan de Déu)
Garcia-Campayo, Javier (RedIAPP (Red de Investigación en Actividades Preventivas y Promoción de la Salud))
Montero-Marín, Jesús (University of Oxford. Department of Psychiatry)
Feliu-Soler, Albert (Universitat Autònoma de Barcelona. Facultat de Psicologia)

Fecha:	2020
Resumen:	The lack of highly effective treatments for fibromyalgia (FM) represents a great challenge for public health. The objective of this parallel, pilot randomized controlled trial (RCT) was two-fold: (1) to analyze the clinical effects of mindfulness plus amygdala and insula retraining (MAIR) compared to a structurally equivalent active control group of relaxation therapy (RT) in the treatment of FM; and (2) to evaluate its impact on immune-inflammatory markers and brain-derived neurotrophic factor (BDNF)in serum. A total of 41 FM patients were randomized into two study arms: MAIR (intervention group)and RT (active control group), both as add-ons of treatment as usual. MAIR demonstrated significantly greater reductions in functional impairment, anxiety, and depression, as well as higher improvements in mindfulness, and self-compassion at post-treatment and follow-up, with moderate to large effectsizes. Significant decreases in pain catastrophizing and psychological inflexibility and improvementsin clinical severity and health-related quality of life were found at follow-up, but not at post-treatment,showing large effect sizes. The number needed to treat was three based on the criteria of ≥50% Fibromyalgia Impact Questionnaire (FIQ) reduction post-treatment. Compared to RT, the MAIRshowed significant decreases in BDNF. No effect of MAIR was observed in immune-inflammatorybiomarkers (i. e. , TNF-α, IL-6, IL-10, and hs-CRP). In conclusion, these results suggest that MAIR, as an adjuvant of treatment-as-usual (TAU), appears to be effective for the management of FM symptomsand for reducing BDNF levels in serum.
Ayudas:	Instituto de Salud Carlos III RD16/0007/0005 Instituto de Salud Carlos III CPII19/00003 Instituto de Salud Carlos III FI20/00034
Derechos:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Lengua:	Anglès
Documento:	Article ; recerca ; Versió publicada
Materia:	Fibromyalgia ; Mindfulness ; Amygdala and insula retraining ; Mind-body techniques ; Multicomponent intervention ; Brain-derived neurotrophic factor ; Immune-inflammatory markers ; Randomized controlled trial ; Pilot study
Publicado en:	Journal of clinical medicine, Vol. 9 Núm. 10 (2020) , p. 3246, ISSN 2077-0383

Adreça alternativa: https://www.mdpi.com/2077-0383/9/10/3246
DOI: 10.3390/jcm9103246
PMID: 33050630

16 p, 611.7 KB

El registro aparece en las colecciones:
Artículos > Artículos de investigación
Artículos > Artículos publicados